Glucocorticoid-induced osteoporosis: Who to treat with what agent?

Nature Reviews Rheumatology

Volumn 11, Issue 2, 2015, Pages 98-109

  Rizzoli, René ^a   Biver, Emmanuel ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; PLACEBO; PREDNISOLONE; RALOXIFENE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID; VITAMIN;

AGE DISTRIBUTION; BONE DENSITY; CORRELATIONAL STUDY; CORTICOSTEROID THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; FOLLOW UP; GLUCOCORTICOID INDUCED OSTEOPOROSIS; HUMAN; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOPHYSIOLOGY; PATIENT MONITORING; PATIENT SAFETY; PRACTICE GUIDELINE; PREMENOPAUSE; REVIEW; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT INDICATION; BONE; BONE DEVELOPMENT; CHEMICALLY INDUCED; DRUG EFFECTS; FRAGILITY FRACTURE; INTESTINE ABSORPTION; PATIENT SELECTION; PHYSIOLOGY;

BONE AND BONES; BONE DEVELOPMENT; CALCIUM; DIPHOSPHONATES; GLUCOCORTICOIDS; HUMANS; INTESTINAL ABSORPTION; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; PATIENT SELECTION; VITAMINS;

EID: 84923210501     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2014.188     Document Type: Review

References (114)

1. van Staa, T. P. et al. Use of oral corticosteroids in the United Kingdom. QJM 93, 105-111 (2000).
2. Walsh, L. J., Wong, C. A., Pringle, M. & Tattersfield, A. E. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ 313, 344-346 (1996).
3. Diez-Perez, A. et al. Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49, 493-498 (2011).
4. Overman, R. A., Yeh, J. Y. & Deal, C. L. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. (Hoboken) 65, 294-298 (2013).
5. Gudbjornsson, B., Juliusson, U. I. & Gudjonsson, F. V. Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice. Ann. Rheum. Dis. 61, 32-36 (2002).
6. van Staa, T. P., Leufkens, H. G. & Cooper, C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos. Int. 13, 777-787 (2002).
7. Kanis, J. A. et al. A meta-analysis of prior corticosteroid use and fracture risk. J. Bone Miner. Res. 19, 893-899 (2004).
8. van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 39, 1383-1389 (2000).
9. Steinbuch, M., Youket, T. E. & Cohen, S. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos. Int. 15, 323-328 (2004).
10. van Staa, T. P., Leufkens, H. G. & Cooper, C. Does a fracture at one site predict later fractures at other sites? A British cohort study. Osteoporos. Int. 13, 624-629 (2002).
11. Canalis, E., Mazziotti, G., Giustina, A. & Bilezikian, J. P. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319-1328 (2007).
12. van Staa, T. P., Leufkens, H. G., Abenhaim, L., Zhang, B. & Cooper, C. Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 993-1000 (2000).
13. van Staa, T. P., Leufkens, H. G. & Cooper, C. Use of inhaled corticosteroids and risk of fractures. J. Bone Miner. Res. 16, 581-588 (2001).
14. Leib, E. S. et al. Official positions for FRAX® clinical regarding glucocorticoids: the impact of the use of glucocorticoids on the estimate by FRAX® of the 10 year risk of fracture from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®. J. Clin. Densitom. 14, 212-219 (2011).
15. Etminan, M., Sadatsafavi, M., Ganjizadeh Zavareh, S., Takkouche, B. & FitzGerald, J. M. Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf. 31, 409-414 (2008).
16. van Staa, T. P., Bishop, N., Leufkens, H. G. & Cooper, C. Are inhaled corticosteroids associated with an increased risk of fracture in children? Osteoporos. Int. 15, 785-791 (2004).
17. Loke, Y. K., Cavallazzi, R. & Singh, S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-analysis of randomised controlled trials and observational studies. Thorax 66, 699-708 (2011).
18. Bijlsma, J. W., Duursma, S. A., Bosch, R., Raymakers, J. A. & Huber-Bruning, O. Acute changes in calcium and bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Br. J. Rheumatol. 27, 215-219 (1988).
19. Bijlsma, J. W., Duursma, S. A. & Huber-Bruning, O. Bone metabolism during methylprednisolone pulse therapy in rheumatoid arthritis. Ann. Rheum. Dis. 45, 757-760 (1986).
20. van der Veen, M. J. & Bijlsma, J. W. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. Clin. Rheumatol. 11, 388-392 (1992).
21. McEvoy, C. E. et al. Association between corticosteroid use and vertebral fractures in older men with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 157, 704-709 (1998).
22. De Vries, F. et al. Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum. 56, 208-214 (2007).
23. Leonard, M. B. et al. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N. Engl. J. Med. 351, 868-875 (2004).
24. Kanis, J. A., Stevenson, M., McCloskey, E. V., Davis, S. & Lloyd-Jones, M. Glucocorticoid-nduced osteoporosis: a systematic review and cost-utility analysis. Health Technol. Assess. 11, 1-231 (2007).
25. Compston, J. Management of glucocorticoid-nduced osteoporosis. Nat. Rev. Rheumatol. 6, 82-88 (2010).
26. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif. Tissue Int. 82, 249-257 (2008).
27. Weinstein, R. S. Clinical practice. Glucocorticoidnduced bone disease. N. Engl. J. Med. 365, 62-70 (2011).
28. Ton, F N., Gunawardene, S. C, Lee, H. & Neer, R. M. Effects of low-dose prednisone on bone metabolism. J. Bone Miner. Res. 20, 464-470 (2005).
29. Hayashi, K. et al. BMP/Wnt antagonists are upregulated by dexamethasone in osteoblasts and reversed by alendronate and PTH: potential therapeutic targets for glucocorticoid-induced osteoporosis. Biochem. Biophys. Res. Commun. 379, 261-266 (2009).
30. Yao, W. et al. Glucocorticoid excess in mice results in early activation of osteoclastogenesis and adipogenesis and prolonged suppression of osteogenesis: a longitudinal study of gene expression in bone tissue from glucocorticoid-treated mice. Arthritis Rheum. 58, 1674-1686 (2008).
31. den Uyl, D., Bultink, I. E. & Lems, W. F Advances in glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 13, 233-240 (2011).
32. Hofbauer, L. C. & Rauner, M. Minireview: live and let die: molecular effects of glucocorticoids on bone cells. Mol. Endocrinol. 23, 1525-1531 (2009).
33. Wijenayaka, A. R. et al. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS ONE 6, e25900 (2011).
34. O'Brien, C. A., Nakashima, T. & Takayanagi, H. Osteocyte control of osteoclastogenesis. Bone 54, 258-263 (2013).
35. Weinstein, R. S., Jilka, R. L., Parfitt, A. M. & Manolagas, S. C. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102, 274-282 (1998).
36. Kroger, H., Honkanen, R., Saarikoski, S. & Alhava, E. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis-a population based study. Ann. Rheum. Dis. 53, 18-23 (1994).
37. Roux, C. Are glucocorticoids really deleterious to bone health? Joint Bone Spine 78 (Suppl. 2), S211-S213 (2011).
38. Vedi, S., Elkin, S. L. & Compston, J. E. A histomorphometric study of cortical bone of the iliac crest in patients treated with glucocorticoids. Calcif. Tissue Int. 77, 79-83 (2005).
39. Zebaze, R. M. et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375, 1729-1736 (2010).
40. Compston, J. E. Emerging consensus on prevention and treatment of glucocorticoid-induced osteoporosis. Curr. Rheumatol. Rep. 9, 78-84 (2007).
41. Saag, K. G. et al. Trends in prevention of glucocorticoid-induced osteoporosis. J. Rheumatol. 33, 1651-1657 (2006).
42. Majumdar, S. R. et al. Population-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998-2008). J. Clin. Endocrinol. Metab. 97, 1236-1242 (2012).
43. Overman, C. L. et al. Change of psychological distress and physical disability in patients with rheumatoid arthritis over the last two decades. Arthritis Care Res. (Hoboken) 66, 671-678 (2014).
44. Grossman, J. M. et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. (Hoboken) 62, 1515-1526 (2010).
45. Lekamwasam, S. et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos. Int. 23, 2257-2276 (2012).
46. Compston, J. et al. Recommendations for the registration of agents for prevention and treatment of glucocorticoid-induced osteoporosis: an update from the Group for the Respect of Ethics and Excellence in Science. Osteoporos. Int. 19, 1247-1250 (2008).
47. WHO Collaborating Centre for Metabolic Bone Diseases. FRAX®: WHO Fracture Risk Assessment Tool [online], http://www.sheffield.ac.uk/FRAX /(2014).
48. Kanis, J. A., Johnell, O., Oden, A., Johansson, H. & McCloskey, E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int. 19, 385-397 (2008).
49. Kanis, J. A. et al. Case finding for the management of osteoporosis with FRAX®- assessment and intervention thresholds for the UK. Osteoporos. Int. 19, 1395-1408 (2008).
50. Kanis, J. A., Johansson, H., Oden, A. & McCloskey, E. V. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos. Int. 22, 809-816 (2011).
51. Pereira, R. M. et al. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis. Rev. Bras. Reumatol. 52, 580-593 (2012).
52. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis (National Osteoporosis Foundation, Washington DC, 2014).
53. Cohen, S. et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42, 2309-2318 (1999).
54. Saag, K. G. et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N. Engl. J. Med. 339, 292-299 (1998).
55. Wallach, S. et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif. Tissue Int. 67, 277-285 (2000).
56. Langdahl, B. L. et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos. Int. 20, 2095-2104 (2009).
57. Losada, I. et al. Bisphosphonates in patients with autoimmune rheumatic diseases: can they be used in women of childbearing age? Autoimmun. Rev. 9, 547-552 (2010).
58. van Staa, T. P. et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 48, 3224-3229 (2003).
59. Cooper, C., Dennison, E. M., Leufkens, H. G., Bishop, N. & van Staa, T. P. Epidemiology of childhood fractures in Britain: a study using the general practice research database. J. Bone Miner. Res. 19, 1976-1981 (2004).
60. Bianchi, M. L. Glucocorticoids and bone: some general remarks and some special observations in pediatric patients. Calcif. Tissue Int. 70, 384-390 (2002).
61. Marini, J. C. Do bisphosphonates make children's bones better or brittle? N. Engl. J. Med. 349, 423-426 (2003).
62. Dore, R. K. How to prevent glucocorticoid-induced osteoporosis. Cleve. Clin. J. Med. 77, 529-536 (2010).
63. Inoue, Y. et al. Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin. Rheumatol. 27, 909-912 (2008).
64. Nakhla, M. et al. Bioavailability and short-term tolerability of alendronate in glucocorticoid-treated children. Clin. Ther. 33, 1516-1523 (2011).
65. Ward, L. et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database of Systematic Reviews 2007, Issue 4, Art. No.: CD005324. http://dx.doi.org/10.1002/14651858. CD005324.pub2.
66. Compston, J. Clinical question: what is the best approach to managing glucocorticoid-induced osteoporosis? Clin. Endocrinol. (Oxf.) 74, 547-550 (2011).
67. Devogelaer, J. P. et al. Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club. Osteoporos. Int. 17, 8-19 (2006).
68. Bischoff-Ferrari, H. A. et al. Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials. BMJ 339, b3692 (2009).
69. Amin, S., LaValley, M. P., Simms, R. W. & Felson, D. T. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum. 42, 1740-1751 (1999).
70. Homik, J. et al. Calcium and vitamin D for corticosteroid-induced osteoporosis. Cochrane Database of Systematic Reviews 1998, Issue 2, Art. No.: CD000952. http://dx.doi.org/10.1002/14651858.CD000952.
71. Bolland, M. J., Grey, A. & Reid, I. R. Differences in overlapping meta-analyses of vitamin D supplements and falls. J. Clin. Endocrinol. Metab. http://dx.doi.org/10.1210/jc.2014-2562.
72. de Nijs, R. N. et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 355, 675-684 (2006).
73. 3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos. Int. 15, 589-602 (2004).
74. Adachi, J. D. et al. Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202-211 (2001).
75. Shane, E. et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. N. Engl. J. Med. 350, 767-776 (2004).
76. Takeda, S., Kaneoka, H. & Saito, T. Effect of alendronate on glucocorticoid-induced osteoporosis in Japanese women with systemic autoimmune diseases: versus alfacalcidol. Mod. Rheumatol. 18, 271-276 (2008).
77. Hollick, R. J. & Reid, D. M. Role of bisphosphonates in the management of postmenopausal osteoporosis: an update on recent safety anxieties. Menopause Int. 17, 66-72 (2011).
78. Rizzoli, R. et al. Management of glucocorticoid-induced osteoporosis. Calcif. Tissue Int. 91, 225-243 (2012).
79. Sambrook, P. N. et al. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate. Bone 50, 289-295 (2012).
80. Gluer, C. C. et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. J. Bone Miner. Res. 28, 1355-1368 (2013).
81. Adachi, J. D. et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N. Engl. J. Med. 337, 382-387 (1997).
82. Reid, D. M. et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner. Res. 15, 1006-1013 (2000).
83. Reid, D. M., Adami, S., Devogelaer, J. P. & Chines, A. A. Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy. Calcif. Tissue Int. 69, 242-247 (2001).
84. Reid, D. M. et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 373, 1253-1263 (2009).
85. Devogelaer, J. P. et al. Baseline glucocorticoid dose and bone mineral density response with teriparatide or alendronate therapy in patients with glucocorticoid-induced osteoporosis. J. Rheumatol. 37, 141-148 (2010).
86. Saag, K. G. et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N. Engl. J. Med. 357, 2028-2039 (2007).
87. Saag, K. G. et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 60, 3346-3355 (2009).
88. Farahmand, P. et al. Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis. Osteoporos. Int. 24, 2971-2981 (2013).
89. Lane, N. E. et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J. Clin. Invest. 102, 1627-1633 (1998).
90. Boutsen, Y., Jamart, J., Esselinckx, W., Stoffel, M. & Devogelaer, J. P. Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial. Calcif. Tissue Int. 61, 266-271 (1997).
91. Boutsen, Y., Jamart, J., Esselinckx, W. & Devogelaer, J. P. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J. Bone Miner. Res. 16, 104-112 (2001).
92. Ringe, J. D., Dorst, A., Faber, H., Ibach, K. & Sorenson, F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14, 801-807 (2003).
93. Mok, C. C. et al. Raloxifene for prevention of glucocorticoid-induced bone loss: a 12-month randomised double-blinded placebo-controlled trial. Ann. Rheum. Dis. 70, 778-784 (2011).
94. Hofbauer, L. C. et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140, 4382-4389 (1999).
95. Sivagurunathan, S., Muir, M. M., Brennan, T. C., Seale, J. P. & Mason, R. S. Influence of glucocorticoids on human osteoclast generation and activity. J. Bone Miner. Res. 20, 390-398 (2005).
96. Vidal, N. O., Brandstrom, H., Jonsson, K. B. & Ohlsson, C. Osteoprotegerin mRNA is expressed in primary human osteoblast-like cells: down-regulation by glucocorticoids. J. Endocrinol. 159, 191-195 (1998).
97. Weinstein, R. S. et al. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. Endocrinology 152, 3323-3331 (2011).
98. Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231-1234 (2011).
99. Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235-1241 (2011).
100. Cohen, S. B. et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 58, 1299-1309 (2008).
101. Dore, R. K. et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann. Rheum. Dis. 69, 872-875 (2010).
102. Jia, J. et al. Glucocorticoid dose determines osteocyte cell fate. FASEB J. 25, 3366-3376 (2011).
103. Stoch, S. A. & Wagner, J. A. Cathepsin K inhibitors: a novel target for osteoporosis therapy. Clin. Pharmacol. Ther 83, 172-176 (2008).
104. Eisman, J. A. et al. Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect. J. Bone Miner. Res. 26, 242-251 (2011).
105. van Lierop, A. H., Hamdy, N. A. & Papapoulos, S. E. Glucocorticoids are not always deleterious for bone. J. Bone Miner. Res. 25, 2796-2800 (2010).
106. Gerber, A. N., Masuno, K. & Diamond, M. I. Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc. Natl Acad. Sci. USA 106, 4929-4934 (2009).
107. Rauch, A. et al. An anti-inflammatory selective glucocorticoid receptor modulator preserves osteoblast differentiation. FASEB J. 25, 1323-1332 (2011).
108. Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of Physicians. Glucocorticoid-induced osteoporosis: guidelines for prevention and treatment (RCP, London, 2002).
109. Geusens, P. P. et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann. Rheum. Dis. 63, 324-325 (2004).
110. Nawata, H. et al. Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004). J. Bone Miner. Metab. 23, 105-109 (2005).
111. Dachverband Osteologie. DVO guideline 2009 for prevention, diagnosis and therapy of osteoporosis in adults. Osteologie 20, 55-74 (2011).
112. Papaioannou, A. et al. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 182, 1864-1873 (2010).
113. Compston, J. et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013. Maturitas 75, 392-396 (2013).
114. No authors listed. Actualisation 2012 des recommandations françaises du traitement médicamenteux de l'ostéoporose po-ménopausique [online], http://www.grio.org/documents/journee-scientifique-27-413-1390825162.pdf